-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Financial App News, Cinda Biotech (01801.HK) announced that Cindilizumab (European product name: Zybrivo®) has received the first positive opinion from the European Medicines Agency (EMA) Commission for Human Medicines (CHMP). The CHMP recommended approval of cindilizumab combination chemotherapy for adult patients with advanced non-squamous non-small cell lung cancer (NSCLC). If approved by the European Commission, Zybrivo will expand first-line treatment options for lung cancer patients in Europe. Cindilizumab is an immunotherapeutic drug. It is an all-human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed cell death protein 1 (PD-1).
Share
Listen to the news
Zhitong Financial App News, Cinda Biotech (01801.HK) announced that Cindilizumab (European product name: Zybrivo®) has received the first positive opinion from the European Medicines Agency (EMA) Commission for Human Medicines (CHMP). The CHMP recommended approval of cindilizumab combination chemotherapy for adult patients with advanced non-squamous non-small cell lung cancer (NSCLC). If approved by the European Commission, Zybrivo will expand first-line treatment options for lung cancer patients in Europe. Cindilizumab is an immunotherapeutic drug. It is an all-human immunoglobulin G4 (IgG4) monoclonal antibody that binds to programmed cell death protein 1 (PD-1).
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending